Blood Sample Analysis in Predicting Overall Survival in Patients With Recurrent or Metastatic Head and Neck Cancer

ECOG-ACRIN Cancer Research Group

Status: Completed

Conditions: Head and Neck Cancer

Treatments: Other: matrix-assisted laser desorption/ionization time of flight mass spectrometry

Study type: Observational

Funder types: NETWORK; NIH

Identifiers

NCT00898911

ECOG-E3301T1

CDR0000600560

Details and patient eligibility

About

RATIONALE: Studying samples of blood in the laboratory from patients with cancer may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors predict how patients will respond to treatment.

PURPOSE: This research study is looking at blood sample analysis in predicting overall survival in patients with recurrent or metastatic head and neck cancer.

Full description

OBJECTIVES:

• To validate the mass spectrometry profile that is predictive of survival benefit in patients with recurrent or metastatic head and neck squamous cell carcinoma treated with EGFR inhibitors.

OUTLINE: Plasma and serum samples are analyzed by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry and classified according to prognosis ("good" vs "poor") using a previously developed predictive algorithm.

Enrollment: 30 patients

Sex: All

Ages: 18 to 120 years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

DISEASE CHARACTERISTICS:

• Diagnosis of recurrent or metastatic head and neck squamous cell carcinoma

• Meets 1 of the following criteria:

  • Enrolled on clinical trial ECOG-E3301 and previously treated with irinotecan hydrochloride and docetaxel
  • Enrolled on clinical trial VU-VICC-HN-0501 and previously treated with docetaxel and bortezomib

• Plasma and serum samples available for analysis

PATIENT CHARACTERISTICS:

• Not specified

PRIOR CONCURRENT THERAPY:

• See Disease Characteristics